Why Billing Compliance Matters for PE Healthcare Operations
Billing compliance is not optional for PE-backed healthcare groups. One compliance failure can lead to massive fines, legal action, and damage to the entire portfolio's reputation.
Peptide therapy billing carries extra compliance risk because of evolving regulations and the use of compounded products. PE firms must make compliance a top priority from day one.
Daniel R. Levinson, Former Inspector General, U.S. Department of Health and Human Services: "Health care fraud is not a victimless crime. It raises the cost of health care for everyone and can put patients at risk"
The Financial Risk of Non-Compliance
The Office of Inspector General (OIG) and the Department of Justice actively investigate healthcare billing fraud. Penalties for violations can reach thousands of dollars per false claim.
For PE-backed groups, a compliance failure at one location can trigger investigations across the entire portfolio. The financial and reputational damage can far exceed the amount of any improper billing.
The False Claims Act allows penalties of over $27,000 per false claim, plus treble damages. A single audit finding involving hundreds of claims can result in multi-million dollar settlements.
The DOJ recovered over $2.2 billion in False Claims Act settlements and judgments from healthcare fraud cases in fiscal year 2024 alone.
Key Compliance Regulations for Peptide Therapy Billing
Several federal laws govern healthcare billing compliance. The False Claims Act, the Anti-Kickback Statute, and the Stark Law are the most important ones to understand.
HIPAA also plays a role because billing data contains protected health information. Your billing team must handle patient data in compliance with HIPAA privacy and security rules.
The False Claims Act and Peptide Therapy
The False Claims Act makes it illegal to submit a claim to a government payer that you know is false or fraudulent. This includes claims with incorrect codes, inflated charges, or services that were not provided.
Even unintentional errors can lead to False Claims Act liability if they result from reckless disregard for accuracy. This is why training and quality controls are so important.
The Anti-Kickback Statute
The Anti-Kickback Statute prohibits offering or receiving anything of value in exchange for patient referrals. This is relevant for PE healthcare groups that may have complex referral relationships.
Be careful with any arrangements that could look like they are paying for referrals. Compensation models, marketing agreements, and vendor relationships should all be reviewed for Anti-Kickback compliance.
PE-backed healthcare groups should have legal counsel review all referral arrangements and compensation structures for Anti-Kickback Statute compliance. Violations can result in criminal penalties and exclusion from federal healthcare programs.
Stark Law Considerations
The Stark Law prohibits physicians from referring patients for certain services to entities with which they have a financial relationship. This applies to many of the services involved in peptide therapy.
PE-backed groups with physician ownership or compensation arrangements must ensure these relationships comply with Stark Law exceptions. Non-compliance can result in claim denials and refund obligations.
Building a Compliance Program
Every PE healthcare portfolio should have a formal compliance program. The OIG has published guidance on the seven essential elements of an effective compliance program.
These elements include written policies, a compliance officer, training, reporting mechanisms, auditing, enforcement, and corrective action. Each element plays a role in preventing and detecting billing problems.
Written Compliance Policies and Procedures
Your compliance policies should cover every aspect of the billing process. They should address coding accuracy, documentation requirements, claim submission standards, and how to handle errors.
Policies must be specific to peptide therapy billing, not just general healthcare billing. Review and update them at least once a year or whenever regulations change.
The OIG recommends that healthcare organizations update their compliance policies annually and conduct a formal risk assessment at least every two years to identify emerging compliance threats.
Appointing a Compliance Officer
A dedicated compliance officer oversees the compliance program and reports to senior leadership. This person should have the authority and resources needed to do the job effectively.
For PE portfolios, the compliance officer should have visibility across all locations. They should be independent from the billing and operations teams to avoid conflicts of interest.
Training Your Team on Compliance
Every person involved in the billing process needs compliance training. This includes providers, coders, billers, front desk staff, and management.
Training should be conducted at hire and at least annually after that. Cover topics like proper coding, documentation standards, how to report suspected violations, and the consequences of non-compliance.
Assign a dedicated compliance officer at each portfolio location to run quarterly internal audits of peptide therapy billing codes, focusing on modifier usage and documentation completeness for compounded products.
Internal Auditing for Peptide Therapy Billing
Regular internal audits are your best defense against compliance problems. Audits should review a sample of peptide therapy claims for coding accuracy, documentation support, and proper billing practices.
Conduct audits at least quarterly and increase the frequency if problems are found. Use audit results to update training materials and improve processes.
Responding to Compliance Issues
When a compliance issue is found, your team must act quickly. Investigate the scope of the problem, correct any errors, and implement changes to prevent it from happening again.
Self-disclosure to the OIG may be appropriate for significant issues. Having a clear response protocol helps your team handle compliance problems efficiently and transparently.
A strong compliance program does not just prevent problems. It also demonstrates good faith, which can reduce penalties if an issue is discovered by regulators.
Coding Compliance for Peptide Therapy
Coding compliance means using the right codes for the services that were actually provided. Upcoding, unbundling, and using incorrect modifiers are all compliance violations. For additional context, the NIH National Institute on Aging research offers relevant guidance on this topic.
Your coding team should follow official coding guidelines and payer-specific rules. Regular coding audits help ensure accuracy and catch errors before they become compliance problems.
Documentation Compliance
Documentation must support every code on every claim. If the documentation does not support the code, the claim is considered false even if the service was actually provided.
Implement documentation templates that prompt providers to capture all required elements. Audit documentation regularly to ensure it meets compliance standards.
Compounded Peptide Compliance Issues
Compounded peptide products present unique compliance challenges. Billing for compounded drugs requires careful attention to coding, documentation, and payer rules.
Some compounded peptide products may not be eligible for insurance reimbursement at all. Billing for non-covered compounded products can create compliance risk if not handled properly.
Compliance Reporting and Whistleblower Protections
Your compliance program must include a way for employees to report suspected violations without fear of retaliation. An anonymous hotline or reporting system encourages people to speak up.
Federal law protects whistleblowers who report healthcare fraud. PE-backed groups should make it clear that retaliation against whistleblowers will not be tolerated.
Managing Compliance Across a PE Portfolio
Compliance standards must be consistent across all locations in the portfolio. A single location operating out of compliance can expose the entire organization to risk.
Centralize compliance oversight and conduct regular cross-location audits. Standardize policies, training, and reporting across the portfolio.
Working with External Compliance Experts
Outside compliance consultants and legal counsel bring specialized expertise. They can conduct independent audits, review policies, and help your team stay current with regulatory changes.
PE-backed groups should engage external compliance experts at least annually. An independent perspective helps identify blind spots that internal teams may miss.
PE healthcare groups must treat billing compliance as a portfolio-wide discipline, not a site-level afterthought, because a single location's violations can trigger audits and liability across every entity in the portfolio.
Frequently Asked Questions
What are the biggest compliance risks in peptide therapy billing?
The biggest risks include incorrect coding (upcoding or unbundling), inadequate documentation, billing for non-covered compounded products, and violations of the Anti-Kickback Statute or Stark Law in referral arrangements.
How often should we audit our peptide therapy billing?
Internal audits should be conducted at least quarterly, with a larger sample size for high-risk areas like peptide therapy. If problems are found, increase the frequency until the issues are resolved.
Who should be responsible for compliance in a PE healthcare portfolio?
A dedicated compliance officer with authority and independence should lead the program. This person should report directly to senior leadership and have visibility across all portfolio locations.
What happens if a compliance violation is found?
Investigate the scope of the issue immediately, correct any billing errors, and implement process changes to prevent recurrence. For significant issues, consider voluntary self-disclosure to the OIG, which can reduce penalties.
Do all employees need compliance training?
Yes, everyone involved in the billing process needs compliance training, including providers, coders, billers, and administrative staff. Training should happen at hire and at least annually after that.
Protect Your Portfolio with PeptideStaff
Compliance starts with having the right people on your team. PeptideStaff places billing and compliance professionals who understand both peptide therapy and the regulatory demands of PE-backed healthcare.
Contact PeptideStaff today to find compliance-savvy billing talent for your healthcare portfolio. We help you build a team that keeps your operations clean and your revenue protected.
Topics
Jennifer Walsh
Senior Healthcare Staffing Consultant
RN, BSN | 13 years placing clinical professionals in wellness practices
Registered nurse and staffing specialist who has placed over 400 clinical professionals across peptide therapy, hormone optimization, and integrative medicine clinics. Expertise in credentialing and retention strategy.
Reviewed by Jennifer Walsh, RN, April 2026